
CBAY
Healthcare · Biotechnology · $3.73B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · +3.2% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 28, 2024 | After the close | -0.31 | -0.35 | -12.9% |
| Nov 7, 2023 | After the close | -0.29 | -0.32 | -10.3% |
| Aug 10, 2023 | After the close | -0.20 | -0.01 | +95.0% |
| May 15, 2023 | After the close | -0.09 | -0.29 | -222.2% |
| Mar 16, 2023 | After the close | -0.30 | -0.30 | 0.0% |
| Nov 14, 2022 | After the close | -0.30 | -0.28 | +6.7% |
| Aug 11, 2022 | After the close | -0.30 | -0.31 | -3.3% |
| May 12, 2022 | After the close | -0.31 | -0.32 | -3.2% |
| Mar 17, 2022 | After the close | -0.26 | -0.34 | -30.8% |
| Nov 10, 2021 | After the close | -0.26 | -0.33 | -26.9% |
| Aug 12, 2021 | After the close | -0.27 | -0.34 | -25.9% |
| May 13, 2021 | After the close | -0.24 | -0.25 | -4.2% |
| Mar 25, 2021 | After the close | -0.20 |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119…
| -0.23 |
| -15.0% |
| Nov 5, 2020 | After the close | -0.17 | -0.17 | 0.0% |
| Aug 10, 2020 | After the close | -0.24 | -0.16 | +33.3% |
| May 11, 2020 | After the close | -0.30 | -0.19 | +36.7% |
| Mar 12, 2020 | After the close | -0.39 | -0.35 | +10.3% |
| Nov 5, 2019 | After the close | -0.37 | -0.38 | -2.7% |
| Aug 7, 2019 | After the close | -0.37 | -0.35 | +5.4% |
| May 8, 2019 | After the close | -0.34 | -0.37 | -8.8% |
| Feb 28, 2019 | After the close | -0.36 | -0.32 | +11.1% |
| Nov 6, 2018 | After the close | -0.29 | -0.31 | -6.9% |
| Aug 9, 2018 | After the close | -0.25 | -0.29 | -16.0% |
| May 8, 2018 | After the close | -0.14 | -0.32 | -128.6% |
| Mar 15, 2018 | After the close | -0.19 | -0.11 | +42.1% |